Drug intelligence / Profile preview

Hanmi Tams

Development stage: Phase 1
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Hanmi Tams is a tamsulosin-based pharmaceutical formulation developed and marketed by Hanmi Pharmaceutical Company Limited for the management of benign prostatic hyperplasia (BPH). As a selective antagonist of alpha-1A and alpha-1B adrenergic receptors, it works by relaxing the smooth muscle in the prostate gland and the bladder neck, which facilitates improved urinary flow and alleviates lower urinary tract symptoms (LUTS). Specifically tailored for the Korean market, Hanmi Tams is available as a capsule and has been evaluated in real-world observational studies to confirm its safety profile and clinical effectiveness in adult males.

Brand names: Hanmi TamsHanmi Tams Capsule
Other names: tamsulosin

Targets

ADRA1B (α1B)ADRA1D (α1D)ADRA1A (α1A)

Beyond the preview

Go deeper on Hanmi Tams.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hanmi Tams.

Explore the full profile